News › Pharmaceuticals  ·  25 Mar 2026, 12:52 AM IST  ·  4 months ago

Bearish Risk: Rising Chemical Costs Choke Indian API Makers; Granules, Divi's Lab Under Pressure

VolatileBias: Bearish -7085% confidencePharmaceuticalsChemicalsBearish read

In one line — Given the article's age, the market has likely priced in some of this, but monitor Q4 and Q1 results of API manufacturers for sustained margin pressure; consider short-term bearish bias on API-heavy pharma stocks.

Bearish
Bullish
−1000-70+100

Source: Economic Times · AI-summarised by Anadi · Updated 25 Mar 2026, 9:00 AM IST

Pharmaceuticalstilt negative
Chemicalstilt negative

What Happened

Indian bulk-drug manufacturers are grappling with a severe cost crisis due to a sharp increase in prices of key solvents and intermediates. This surge is attributed to supply chain disruptions stemming from the West Asia conflict, leading to production halts for some units and a more than doubling of paracetamol API prices.

Why It Matters (for you)

This situation is critical for the Indian pharmaceutical sector, which relies heavily on APIs and intermediates. Increased input costs will directly impact the profitability and margins of API manufacturers, potentially leading to higher drug prices for consumers and affecting the competitiveness of Indian pharma exports. The ripple effect could be felt across the entire drug manufacturing value chain.

Impact on Indian Markets

API-focused pharmaceutical companies like Divi's Laboratories (DIVISLAB), Laurus Labs (LAURUSLABS), Granules India (GRANULES), IPCA Laboratories (IPCALAB), and Aurobindo Pharma (AUROPHARMA) are likely to face negative impacts due to higher raw material costs and potential production disruptions. This could lead to margin contraction and downward pressure on their stock prices. Companies with strong backward integration or long-term supply contracts might be relatively less affected.

What Traders Should Watch Next

Traders should closely monitor the upcoming quarterly results of API and bulk drug manufacturers for signs of margin erosion and commentary on input cost trends. Further escalation or de-escalation of the West Asia conflict will be crucial for supply chain stability. Also, watch for any government interventions or policy changes to support the domestic API industry.

Key Evidence

  • India's bulk-drug manufacturers face severe cost crisis.
  • Prices of key solvents and intermediates have surged due to West Asia conflict.
  • Supply disruptions linked to the conflict are causing the price increases.
  • Production halts reported for several units.
  • Paracetamol API prices have more than doubled.
  • The entire pharmaceutical value chain is impacted.